OraSure Executive Resigns, Effective June 30

BETHLEHEM, PA—OraSure Technologies, Inc. announced that Kathleen G. Weber, the company’s Chief Product Officer, has resigned from her position, effective June 30, 2025. The resignation was reported in a recent SEC filing. According to InvestingPro data, this executive change comes as the company maintains a strong financial health score despite recent challenges.

According to the filing, Weber’s decision to leave the company will be treated as a resignation for "Good Reason" under the terms of her existing employment agreement. This designation allows her to receive severance benefits as stipulated in the agreement, contingent upon her execution of a general release of claims against the company and its wholly-owned subsidiary, DNA Genotek Inc.

The employment agreement and its amendments were previously filed with the SEC and are part of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

OraSure Technologies, with a central index key of 0001116463, is incorporated in Delaware and has its principal executive offices located at 220 East First Street, Bethlehem, Pennsylvania. The company’s common stock is listed on The Nasdaq Stock Market LLC under the trading symbol OSUR.

The SEC filing made on May 9, 2025, provides the official documentation of this corporate update. The information regarding this executive change is based on the company’s SEC filing and does not include any subjective assessment or speculative details. The stock currently trades near its 52-week low of $2.42, having declined about 13% in the past week. Get deeper insights and access to comprehensive analysis with InvestingPro’s exclusive research reports.

In other recent news, OraSure Technologies reported its first-quarter 2025 earnings, revealing revenue of $29.9 million, which slightly exceeded analyst expectations of $29.65 million. The company’s earnings per share (EPS) also beat forecasts, with a reported loss of $0.18 per share compared to the anticipated loss of $0.205. Despite these positive results, Evercore ISI analyst Vijay Kumar downgraded OraSure’s stock price target from $4 to $3, though he maintained an In Line rating. OraSure’s diagnostic products segment showed an 8% year-over-year growth, generating $17.7 million in revenue, while Sample Management Solutions revenue decreased by 16% to $9.1 million.

The company ended the first quarter with a robust cash position of $248 million and no debt, positioning it well for future investments. Looking forward, OraSure has set a revenue guidance range of $28.5 million to $32.5 million for the second quarter of 2025, which is slightly below market expectations. The company is focusing on expanding its B2B2C testing markets and exploring mergers and acquisitions as potential growth avenues. Additionally, OraSure is advancing its product innovation pipeline with upcoming FDA submissions, including a test for chlamydia and gonorrhea. The company faces some challenges, such as potential disruptions in international diagnostics due to changes in USAID/PEPFAR funding.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.